Histone methyltransferase NSD2 mediates the survival and invasion of triple-negative breast cancer cells via stimulating ADAM9-EGFR-AKT signaling

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Acta Pharmacologica Sinica

• Publication date

  2019-01-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41401-018-0199-zPMID 30670815PMCID PMC6786427
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2

  2018cited by this paper
• TGF‐β transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK/Sp1 signaling pathways

  2018cited by this paper
• Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.

  2017cited by this paper
• ZNF516 suppresses EGFR by targeting the CtBP/LSD1/CoREST complex to chromatin

  2017cited by this paper
• Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.

  2016cited by this paper
• Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

  2016cited by this paper
• A perspective on anti-EGFR therapies targeting triple-negative breast cancer.

  2016cited by this paper
• Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen

  2015cited by this paper
• Perspectives on Epidermal Growth Factor Receptor Regulation in Triple-Negative Breast Cancer: Ligand-Mediated Mechanisms of Receptor Regulation and Potential for Clinical Targeting.

  2015cited by this paper
• Unravelling the pivotal role of Alix in MVB sorting and silencing of the activated EGFR.

  2015cited by this paper
• DNMT1–MicroRNA126 Epigenetic Circuit Contributes to Esophageal Squamous Cell Carcinoma Growth via ADAM9–EGFR–AKT Signaling

  2014cited by this paper
• Kinesin Family Deregulation Coordinated by Bromodomain Protein ANCCA and Histone Methyltransferase MLL for Breast Cancer Cell Growth, Survival, and Tamoxifen Resistance

  2014cited by this paper
• Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

  2013cited by this paper
• NSD2 is recruited through its PHD domain to oncogenic gene loci to drive multiple myeloma.

  2013cited by this paper
• Treatment of Triple-Negative Breast Cancer Using Anti-EGFR–Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor

  2013cited by this paper
• Histone Methyltransferase NSD2/MMSET Mediates Constitutive NF-κB Signaling for Cancer Cell Proliferation, Survival, and Tumor Growth via a Feed-Forward Loop

  2012cited by this paper
• New lysine methyltransferase drug targets in cancer

  2012cited by this paper
• TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

  2012cited by this paper
• TIEG1 Inhibits Breast Cancer Invasion and Metastasis by Inhibition of Epidermal Growth Factor Receptor (EGFR) Transcription and the EGFR Signaling Pathway

  2011cited by this paper
• The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors

  2011cited by this paper
• MMSET is highly expressed and associated with aggressiveness in neuroblastoma.

  2011cited by this paper
• The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

  2011cited by this paper
• NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming.

  2011cited by this paper
• Histone lysine methyltransferase Wolf-Hirschhorn syndrome candidate 1 is involved in human carcinogenesis through regulation of the Wnt pathway.

  2011cited by this paper
• ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2.

  2010cited by this paper
• Protein methyltransferases as a target class for drug discovery

  2009cited by this paper
• Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

  2009cited by this paper
• A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf–Hirschhorn syndrome

  2009cited by this paper
• The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.

  2008cited by this paper
• EGFR antagonists in cancer treatment.

  2008cited by this paper
• The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.

  2008cited by this paper
• Angiotensin II and epidermal growth factor receptor cross‐talk mediated by a disintegrin and metalloprotease accelerates tumor cell proliferation of hepatocellular carcinoma cell lines

  2008cited by this paper
• RIP1 links inflammatory and growth factor signaling pathways by regulating expression of the EGFR

  2008cited by this paper
• Up‐regulated expression of ADAM17 in human colon carcinoma: co‐expression with EGFR in neoplastic and endothelial cells

  2005cited by this paper
• Oxidative and Osmotic Stress Signaling in Tumor Cells Is Mediated by ADAM Proteases and Heparin-Binding Epidermal Growth Factor

  2004cited by this paper

• NSD Family-Mediated H3K36 Methylation in Human Cancer: Mechanisms and Therapeutic Opportunities

  2025cites this paper
• Targeting nuclear receptor-binding SET domain protein 2 (NSD2) for cancer therapy: Challenges and emerging strategies.

  2025cites this paper
• Oxalicpyridones A-D, 2-pyridone alkaloids from a marine-derived fungus Penicillium oxalicum suppressing proliferation and metastasis against small cell lung cancer.

  2025cites this paper
• GPR83 protects cochlear hair cells against ibrutinib-induced hearing loss through AKT signaling pathways

  2025cites this paper
• H3K36me2 methyltransferase NSD2/WHSC1 promotes triple-negative breast cancer metastasis via activation of ULK1-dependent autophagy

  2025cites this paper
• CRISPR/Cas9-directed epigenetic editing in colorectal cancer.

  2025cites this paper
• TRPV3 regulates Breast Cancer Cell Proliferation and Apoptosis by EGFR/AKT pathway

  2024cites this paper
• Exploring the oncogenic and tumor-suppressive roles of Circ-ADAM9 in cancer.

  2024cites this paper
• Epithelial NSD2 maintains FMOs-mediated taurine biosynthesis to prevent intestinal barrier disruption

  2024cites this paper
• New insight into the role of the ADAM protease family in breast carcinoma progression

  2024cites this paper
• Epithelial NSD2 maintains FMO‐mediated taurine biosynthesis to prevent intestinal barrier disruption

  2024cites this paper
• Identification of potential methyltransferase NSD2 enzymatic inhibitors through a multi-step structure-based drug design

  2024cites this paper
• Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy.

  2024cites this paper
• Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies.

  2024cites this paper
• Discovery of potent small molecule inhibitors of histone lysine methyltransferase NSDs.

  2024cites this paper
• Multilevel Regulation of NF‐κB Signaling by NSD2 Suppresses Kras‐Driven Pancreatic Tumorigenesis

  2023cites this paper
• MMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Histone Proteomic Networks

  2023cites this paper
• Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2).

  2023cites this paper
• NSD3: Advances in cancer therapeutic potential and inhibitors research.

  2023cites this paper
• Recent advances in nuclear receptor-binding SET domain 2 (NSD2) inhibitors: An update and perspectives.

  2023cites this paper
• Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: Epigenetic mnemonics.

  2022cites this paper
• MMR Deficiency Defines Distinct Molecular Subtype of Breast Cancer with Unique Proteomic Networks and Variable Clinical Significance

  2022cites this paper
• The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors

  2022cites this paper
• From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine

  2022cites this paper
• Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker

  2022cites this paper
• Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond

  2022cites this paper
• Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p/FGF2/PI3K/Akt axis

  2021cites this paper
• NSD2 promotes tumor angiogenesis through methylating and activating STAT3 protein

  2021cites this paper
• Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer

  2021cites this paper
• Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer

  2021cites this paper
• Targeting Histone Modifications in Breast Cancer: A Precise Weapon on the Way

  2021cites this paper
• Targeting the Nuclear Receptor-Binding SET Domain Family of Histone Lysine Methyltransferases for Cancer Therapy: Recent Progress and Perspectives.

  2021cites this paper
• Antitumor effects of 3‐bromoascochlorin on small cell lung cancer via inhibiting MAPK pathway

  2021cites this paper
• ADAM9 Mediates Triple-Negative Breast Cancer Progression via AKT/NF-κB Pathway

  2020cites this paper
• OTT_A_259873 6837..6846

  2020cites this paper
• NSD2 Promotes Tumor Angiogenesis Through Methylating and Activating STAT3 Signaling

  2020cites this paper
• An Overview of ADAM9: Structure, Activation, and Regulation in Human Diseases

  2020cites this paper
• The Role of Methyltransferase NSD2 as a Potential Oncogene in Human Solid Tumors

  2020cites this paper
• Long noncoding RNA CASC9 promotes the proliferation and metastasis of papillary thyroid cancer via sponging miR‐488‐3p

  2020cites this paper
• NSD2 inhibition suppresses metastasis in cervical cancer by promoting TGF-β/TGF-βRI/SMADs signaling.

  2019cites this paper
• Epigenetics of autoimmune liver diseases: current progress and future directions

  2019cites this paper